ABMD News and Press, ABIOMED Inc. From 04/29/21

Image source: The Motley Fool. Abiomed Inc (NASDAQ: ABMD) Q4 2021 Earnings Call Apr 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Abiomed Inc (ABMD) Q4 2021 Earnings Call Transcript

The following slide deck was published by Abiomed, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Abiomed, Inc. 2021 Q4 - Results - Earnings Call Presentation

Abiomed (ABMD) posted fourth-quarter revenue that beat Wall Street estimates, helped by rising demand for its Impella heart pump worldwide.Worldwide Impella heart pump revenue for the quarter increased 17% to $230.4M.The company posted quarterly revenue of $241.2M compared to $206.7M for...

Abiomed (ABMD): Q4 Non-GAAP EPS of $1.07 misses by $0.06; GAAP EPS of $1.24 beats by $0.16.Revenue of $241.25M (+16.7% Y/Y) beats by $10.12M.Press Release For further details see: Abiomed EPS misses by $0.06, beats on revenue

FY 2021 Annual Revenue of $848 Million, Up 1%, with 27.1% Operating Margin during COVID-19 pandemic Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported record fourth quarter fiscal 2021 revenue of $241.2 million comp...

The final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization (PC...

Abiomed (NASDAQ:ABMD) is scheduled to announce FQ4 earnings results on Thursday, April 29th, before market open.The consensus EPS Estimate is $1.13 (+15.3% Y/Y) and the consensus Revenue Estimate is $231.13M (+11.8% Y/Y).Over the last 2 years, ABMD has beaten EPS estimates 100% of the time an...

Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now...

Abiomed shares continue their positive outlook, driven by sales momentum in the Impella 5.0 & 5.5 platforms. Excellent balance sheet management with no debt load signals, high free cash conversion, and equity concentrated capital structure. The company continues to realise net...

Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for ...